A couple of weeks ago the share price was $2 or less. I'm guessing that $2 is what price that CVM could negotiate with whomever big-wig was willing to fork over that much operating capital. It's not the company's focus to maintain a particular share price for short-term traders or newly acquired shareholders looking for a quick score.
It's the company's focus to get Multikine to market, to start generating regular revenue on its own, or to attract interest from a big partner or buy-out pharma. To do that the company needed a sizable chunk of operating capital to keep moving forward. The price to the company for that new chunk of operating capital was a discount for the big investor who could provide that needed capital in the near term.
I bought some new shares this morning at around $2.30. Yeah, sure, they are down even a bit more since then, but I don't focus any money I invest in short-term gains/losses. When Multikine gains regulatory approval - be that in the EU, Great Britain, Canada or with the FDA - that resulting gain in share prices is going to be extremely substantial. Ditto with a buyout - if that's what ends up happening.
How does that recent Warren Buffett quote go: "The stock market is a device for transferring money from the impatient to the patient."
News 
Market Data 
Discover 
